Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 9:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 897 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Systemic Therapy Clear all
Completed Phase 3 Interventional Results available

Clodronate With or Without Chemotherapy and/or Hormonal Therapy in Treating Women With Stage I or Stage II Breast Cancer

NCT00009945
View directory record Official record
Conditions
Breast Cancer
Interventions
clodronate, placebo
Drug
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older · Female only
Enrollment
3,323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2012
U.S. locations
17
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Honolulu, Hawaii + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Sep 6, 2026, 9:41 AM EDT
Terminated Phase 2 Interventional Results available

Treatment of Septic Shock by Inhibiting Autodigestion and Preserving Gut Integrity With Enteric LB1148

NCT02317549
View directory record Official record
Conditions
Septic Shock
Interventions
LB1148, Placebo
Drug
Lead sponsor
Leading BioSciences, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
26
States / cities
Mobile, Alabama • Fresno, California • Long Beach, California + 23 more
Source: ClinicalTrials.gov public record
Updated May 31, 2020 · Synced Sep 6, 2026, 9:41 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Hyaluronidase Via LADD Scleroderma-induced Microstomia

NCT05995626
View directory record Official record
Conditions
Microstomia, Scleroderma
Interventions
Hyaluronidase, CO2 laser
Drug · Device
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
2
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 6, 2026, 9:41 AM EDT
Recruiting Phase 2 Interventional

A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma

NCT05389293
View directory record Official record
Conditions
Follicular Lymphoma, Lymphoma
Interventions
Mosunetuzumab, Zanubrutinib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
9
States / cities
Washington D.C., District of Columbia • Basking Ridge, New Jersey • Hackensack, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 6, 2026, 9:41 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Accelerated Radiation Therapy (ART) to the Breast and Nodal Stations

NCT02917421
View directory record Official record
Conditions
Breast Cancer
Interventions
Radiation
Radiation
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
19 Years to 99 Years · Female only
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Sep 6, 2026, 9:41 AM EDT
Completed Phase 3 Interventional Results available

Vitamin C, Thiamine, and Steroids in Sepsis

NCT03509350
View directory record Official record
Conditions
Sepsis
Interventions
Vitamin C, Thiamine, Hydrocortisone, Vitamin C Placebo, Thiamine Placebo, Hydrocortisone Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
43
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 30 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2021 · Synced Sep 6, 2026, 9:41 AM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus

NCT00381810
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
Rituximab, Methylprednisolone, Acetaminophen, Diphenhydramine
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
16 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
11
States / cities
Paradise Valley, Arizona • San Leandro, California • Boise, Idaho + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2017 · Synced Sep 6, 2026, 9:41 AM EDT
Withdrawn Not applicable Interventional

Carbon-11 Acetate and Fluorine F 18 Sodium Fluoride PET as a Biomarker of Treatment Response in Patients With Hormone Resistant Metastatic Prostate Cancer

NCT02169063
View directory record Official record
Conditions
Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
Interventions
carbon-11 acetate, fluorine F 18 sodium fluoride, positron emission tomography, laboratory biomarker analysis
Radiation · Procedure · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2015
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 30, 2016 · Synced Sep 6, 2026, 9:41 AM EDT
Terminated Phase 2 Interventional Results available

Vitamin D3 Treatment in Pediatric Systemic Lupus Erythematosus

NCT01709474
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Vitamin D3 6000 IU, Vitamin D3 400 IU
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
5 Years to 20 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
13
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2015 · Synced Sep 6, 2026, 9:41 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

An Investigational Scan (hpMRI) for Monitoring Treatment Response in Patients With Thyroid Cancer and Other Malignancies of the Head and Neck Undergoing Radiation Therapy and/or Systemic Therapy

NCT04589624
View directory record Official record
Conditions
Thyroid Gland Carcinoma
Interventions
Hyperpolarized Carbon C 13 Pyruvate, Magnetic Resonance Imaging
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 6, 2026, 9:41 AM EDT
Completed Phase 2 Interventional Results available

Efficacy Study of a Facemask Device to Treat Hypotension

NCT00256724
View directory record Official record
Conditions
Hypotension
Interventions
Impedance Threshold Device, sham ITD
Device
Lead sponsor
Advanced Circulatory Systems
Industry
Eligibility
18 Years to 85 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 30, 2013 · Synced Sep 6, 2026, 9:41 AM EDT
Recruiting Not applicable Interventional

Physical Activity Intervention Among Older Women With Gynecologic Cancers (Fit4Treatment)

NCT05743517
View directory record Official record
Conditions
Ovary Cancer, Endometrial Cancer, Uterine Cancer, Cervical Cancer, Cervix Cancer, Vulvar Cancer, Vaginal Cancer
Interventions
Fit4Treatment
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
60 Years and older · Female only
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Sep 6, 2026, 9:41 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Carfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple Myeloma

NCT01029054
View directory record Official record
Conditions
Multiple Myeloma
Interventions
carfilzomib, lenalidomide plus dexamethasone
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
4
States / cities
Ann Arbor, Michigan • St Louis, Missouri • Hackensack, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2017 · Synced Sep 6, 2026, 9:41 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Primary Systemic Therapy in Operable/Locally Advanced Breast Cancer

NCT00203502
View directory record Official record
Conditions
Breast Cancer
Interventions
Bevacizumab, Cyclophosphamide, Docetaxel
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2015
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated May 10, 2016 · Synced Sep 6, 2026, 9:41 AM EDT
Completed No phase listed Observational

A Study of Treatment Patterns and Outcomes in Participants With Stage IIIA Melanoma Receiving Adjuvant Systemic Therapy

NCT05432622
View directory record Official record
Conditions
Melanoma
Interventions
Not listed
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
The Woodlands, Texas
Source: ClinicalTrials.gov public record
Updated Jan 17, 2024 · Synced Sep 6, 2026, 9:41 AM EDT
Terminated Phase 2 Interventional

Optimization for Regorafenib in HCC

NCT04476329
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Regorafenib 40 MG
Drug
Lead sponsor
SC Liver Research Consortium, LLC
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
9
States / cities
Gilbert, Arizona • Long Beach, California • New Orleans, Louisiana + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2021 · Synced Sep 6, 2026, 9:41 AM EDT
Completed Not applicable Interventional

Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer

NCT00002520
View directory record Official record
Conditions
Bladder Cancer, Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Lung Cancer, Lymphoma, Prostate Cancer, Testicular Germ Cell Tumor, Tobacco Use Disorder, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
nicotine, Usual Care
Drug · Behavioral
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
19 Years to 120 Years
Enrollment
434 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1990
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 14, 2023 · Synced Sep 6, 2026, 9:41 AM EDT
Completed Phase 3 Interventional

Abatacept for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener's)

NCT02108860
View directory record Official record
Conditions
Granulomatosis With Polyangiitis (Wegener's), Granulomatosis With Polyangiitis, Wegener's Granulomatosis, ANCA-Associated Vasculitis
Interventions
Abatacept, placebo
Drug
Lead sponsor
University of South Florida
Other
Eligibility
15 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
10
States / cities
Los Angeles, California • Tampa, Florida • Kansas City, Kansas + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2024 · Synced Sep 6, 2026, 9:41 AM EDT
Terminated Phase 2 Interventional Results available

A Phase 2 Study to Evaluate Axatilimab for Hospitalized Participants With Respiratory Involvement Secondary to COVID-19

NCT04415073
View directory record Official record
Conditions
Coronavirus, COVID, ARDS, Cytokine Storm, Cytokine Release Syndrome
Interventions
SNDX-6352, Placebo
Drug
Lead sponsor
Syndax Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
2
States / cities
Scottsdale, Arizona • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Sep 6, 2026, 9:41 AM EDT
Completed Phase 1 Interventional

Mycophenolate Mofetil to Treat Wegener's Granulomatosis and Related Vascular Inflammatory Conditions

NCT00001764
View directory record Official record
Conditions
Vasculitis, Wegener's Granulomatosis
Interventions
Mycophenolate Mofetil
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 6, 2026, 9:41 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Anti-inflammatory Actions of Osteopathic Manipulative Treatment

NCT04177264
View directory record Official record
Conditions
Inflammation
Interventions
Occipito-Atlantal Decompression (OA DC), Sham Occipito-Atlantal Decompression (Sham OA DC), Splenic Lymphatic Pump Technique (SpLPT), Sham Splenic Lymphatic Pump Technique (Sham SpLPT), Transcutaneous Auricular Vagus Nerve Stimulation (taVNS), Sham Transcutaneous Auricular Vagus Nerve Stimulation (Sham taVNS)
Procedure · Device
Lead sponsor
Burrell College of Health Sciences
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Las Cruces, New Mexico
Source: ClinicalTrials.gov public record
Updated Feb 7, 2023 · Synced Sep 6, 2026, 9:41 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors

NCT03647163
View directory record Official record
Conditions
Solid Tumor, Non Small Cell Lung Cancer, Neuroendocrine Carcinoma, Renal Cell Carcinoma (RCC)
Interventions
VSV-IFNβ-NIS, Pembrolizumab, ipilimumab + nivolumab
Biological
Lead sponsor
Vyriad, Inc.
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
2
States / cities
Rochester, Minnesota • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Sep 6, 2026, 9:41 AM EDT
Completed Phase 3 Interventional Results available

Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer

NCT02492711
View directory record Official record
Conditions
HER-2 Positive Breast Cancer, Metastatic Neoplasm
Interventions
Margetuximab, Trastuzumab, Physician's choice of chemotherapy.
Biological · Drug
Lead sponsor
MacroGenics
Industry
Eligibility
18 Years and older
Enrollment
624 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
62
States / cities
Chandler, Arizona • Gilbert, Arizona • Goodyear, Arizona + 57 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2025 · Synced Sep 6, 2026, 9:41 AM EDT
Completed Phase 3 Interventional Results available

Dopamine Versus Norepinephrine for the Treatment of Vasopressor Dependent Septic Shock

NCT00604019
View directory record Official record
Conditions
Septic Shock
Interventions
Dopamine, Norepinephrine
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 10, 2023 · Synced Sep 6, 2026, 9:41 AM EDT